Background and purpose Adult T-cell leukemia/lymphoma (ATLL) is an aggressive hematological malignancy caused by human T-cell leukemia virus type-1 (HTLV-1); no effective methods have yet been identified to prevent development of ATLL in carriers of HTLV-1. This study investigated the association between cigarette smoking and the risk of ATLL development among Japanese carriers of HTLV-1. Methods This study examined the association between smoking and development of ATLL in a cohort of 1,332 Japanese HTLV-1 carriers aged 40-69 years free of ATLL at baseline from two different HTLV-1-endemic areas of Japan. Cox proportional hazards models adjusted for sex, geographic area, age at baseline, and alcohol drinking were used to estimate the effect of cigarette smoking on ATLL development. Results Between 1993 and 2012, 25 new ATLL cases were identified among these subjects. The overall crude incidence rate for ATLL was 1.08 per 1,000 person-years among HTLV-1 carriers and was higher among male carriers than among female carriers (2.21 vs. 0.74). The risk of ATLL development increased significantly with increasing numbers of cigarettes smoked per day (hazard ratio for every increment of 20 cigarettes, 2.03; 95 % confidence interval (CI) 1.13-3.66 overall, 2.07 (95 % CI 1.13-3.73) in male carriers). Conclusions Cigarette smoking may influence ATLL development among HTLV-1 carriers in Japan.
Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a hematological malignancy associated with human T-cell leukemia virus type 1 (HTLV-1) [1] . HTLV-1 was discovered in the early 1980's, [2, 3] it has been identified worldwide, and an estimated 5-10 million individuals are infected [4] . Southwest Japan [5] , the Caribbean Islands, Central Africa, and South America are considered the primary endemic regions [4] .
HTLV-1 can be transmitted from mother-to-child via breastfeeding, as well as by sexual intercourse or blood transfusions. In Japan, the country with the highest HTLV-1 endemicity worldwide, transmission via blood transfusion has been nearly eliminated through viral screening of donated blood since 1986 [6] . Mother-to-child transmission has also decreased in endemic areas after implementation of programs in 1987 to discourage HTLV-1 carrier mothers from breast-feeding [7] . Nevertheless, approximately one million people are infected with HTLV-1 [8] , and approximately 1,000 new cases of ATLL and 1,000 deaths due to ATLL are reported annually in Japan [9] . Because ATLL is an aggressive entity with poor prognosis, effective therapeutic and preventive strategies are necessary.
Most HTLV-1-infected subjects remain lifelong asymptomatic carriers, but a proportion may progress to ATLL after a long latency period; the cumulative lifetime risk of ATLL was estimated to be 4.0 and 4.2 % for Jamaican males and females, respectively, infected before the age of 20 years [10] . On the other hand, the cumulative incidence of ATLL among HTLV-1 carriers in Japan was estimated at 2.5 % (3-5 % in males, 1-2 % in females) [11] . A variety of risk factors and determinants for progression to ATLL from HTLV-1 carrier status have been reported [12] [13] [14] , including early life exposure to HTLV-1, male sex, advanced age, laboratory abnormalities such as a high levels of soluble interleukin-2 receptor, higher proviral load, and many genetic and epigenetic alterations [15] [16] [17] [18] . However, no definitive factors have yet been identified. Moreover, to our knowledge, no prospective cohort study has identified lifestyle factors associated with ATLL development among HTLV-1 carriers in the general population.
Cigarette smoking is a well-known risk factor for a variety of malignancies, including hematological malignancies [19] . However, no study has prospectively investigated the association between cigarette smoking and ATLL development among HTLV-1 carriers. The present study, therefore, investigated this relationship in asymptomatic HTLV-1 carriers in a long-term population-based cohort study in Japan.
Materials and methods

Study population
The Japan Public Health Center-Based Prospective Study (JPHC study) [20] consists of two cohorts: residents aged 40-59 years from five public health center (PHC) regions who started the study in 1990 (Cohort I) and residents aged 40-69 years from an additional six PHC areas who started in 1993-1994 (Cohort II). The details of these cohorts have been described previously [20] .
This study used Cohort II data. Cohort II (n = 78,825) included 63,216 participants (80 % response rate) who completed a baseline questionnaire on medical history, smoking and drinking habits, etc. Of these, 38.6 % (n = 24,374) voluntarily provided 10 mL blood samples at health checkups during the baseline survey. The blood samples were divided into plasma and buffy layers and preserved at -80°C until analysis. Study participants were informed of the objectives and methods of the study in writing, and those who answered the questionnaire and donated blood were regarded as having provided informed consent to participate. Of these, we selected only those who tested positive for HTLV-1 antibodies and had provided data on their basic characteristics (n = 9,705); moreover, we restricted the study population to only those subjects who were HTLV-1-seropositive, leaving a total of 1,451 subjects. Of these HTLV-1-seropositive subjects, two had already been diagnosed with ATLL before the start of the follow-up period, and 117 had undocumented or incomplete information regarding their smoking and/or drinking habits. Thus, a total of 1,332 Japanese HTLV-1 carriers (344 men and 988 women) were included in the final analysis (Fig. 1) .
Assessment of exposure
Questions on smoking habits included current and former smoking status, age at smoking initiation and quitting, and average number of cigarettes smoked per day. We defined current and former smokers as ever smokers. Smoking intensity for ever smokers was evaluated by the number of cigarettes smoked per day or by pack-years defined by multiplying the number of cigarettes per day divided by 20 by the number of years of smoking.
Questions on drinking habits included current and former drinking status, frequency, types of drinks, and average consumption per day. We defined drinkers with a drinking frequency of 3 or more days per week as regular drinkers. Drinking intensity for regular drinkers was evaluated based on weekly alcohol consumption defined by multiplying the daily amount of ethanol intake by the weekly frequency.
The prevalence of regular drinkers among ever smokers was significantly higher than among never smokers in overall and female, but not in male (Table 1) .
Cohort follow-up and identification of ATLL cases Subjects were followed up from the baseline until 31 December 2012. Changes in residence status, including survival, were identified annually through residential registries. Because the follow-up rate was 99.9 %, selection bias due to participants lost to follow-up was considered negligible.
The JPHC cancer registry identified ATLL cases among the study subjects from two data sources: active patient notification from major local hospitals in the study areas and population-based cancer registries with permission from the local governments responsible for these registries. ATLL cases were coded based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) morphology/behavior code (code: 9827/3) [21] . Death certificates were used as supplementary sources of information. The proportion of cases for which information was only available from death certificates was 8.0 %, indicating satisfactory cancer registry system quality during the study period.
Laboratory assays for HTLV-1
A commercial passive particle agglutination assay common in Japan was used to screen for HTLV-1 antibodies (SERODIA HTLV-I, Fujirebio Inc., Tokyo, Japan).
Statistical methods
Person-years of follow-up were calculated for each person from the date of baseline until the date of ATLL diagnosis, death, moving out of the study area, or the end of followup, whichever occurred first. The baseline factors included in the analyses were age at baseline, sex, geographic area, smoking status or intensity, and drinking intensity. To evaluate the effect of smoking on ATLL development, we used two different Cox proportional hazards models and estimated the hazard ratios (HRs) with 95 % confidence intervals (CIs) [22] . First, ever smokers (former and current smokers) were compared with never smokers. Second, smoking status was treated as ''continuous intensity'' and represented by the number of cigarettes per day or cigarette pack-years. The hazard ratios for ever smokers and for each level of smoking intensity were estimated by univariate and multivariate analysis. Multivariate analyses were adjusted for sex, age at baseline, and weekly alcohol intake after geographic stratification. The proportional hazards assumptions for each covariate were evaluated by a Kolmogorov-type supremum test and applied to all covariates. Furthermore, we performed analyses for males only to clarify the effects of smoking on ATLL development.
All statistical tests were two-sided, and p \ 0.05 were considered statistically significant. The calculations were performed using the PHREG procedure in the SAS software package (version 9.3; SAS Institute, Inc., Cary, NC, USA).
Approval
This study was approved by the Nagasaki University Graduate School of Biomedical Sciences Ethics Committee (Protocol No. 14121245), and the use of JPHC study data was approved by the Ethics Committee of the National Cancer Center, Japan.
Results
A total of 25 cases of ATLL were identified during 22,961 person-years of follow-up from 1993 to 2012 (average follow-up period: 17.2 years) of 1,332 subjects seropositive for HTLV-1 at baseline.
The distributions of baseline characteristics among these HTLV-1 carriers are summarized in Table 1 . The majority of female HTLV-1 carriers were never smokers, whereas never smokers comprised nearly one-quarter of male subjects. Male smokers who belonged to the category equivalent to more than 40 pack-years were slightly older than other male subjects. The proportions of male smokers (former and current) and heavy smokers (]20 cigarettes per day or ]40 pack-years) increased with age. The overall crude incidence rate was 1.08 per 1,000 person-years (PYs) of follow-up. The crude incidence rate was significantly higher in male HTLV-1 carriers (2.21 per 1,000 PYs) than in female carriers (0.74 per 1,000 PYs) ( Table 2) .
Among the two categories of smoking history, ATLL incidence was significantly higher for ever smokers (HR 3.08, 95 % CI 1.38-6.88) than for never smokers in univariate analysis, but not in multivariate analysis (HR 1.64, 95 % CI 0.45-6.06) ( Table 2) .
With respect to the effects of smoking intensities, there were significant increasing risks of ATLL development by increments of each intensity in both univariate and multivariate analysis. Namely, the HRs for every increment of 20 cigarettes smoked per day which was the mean number among ever smokers were 2.37 (95 % CI 1.58-3.52) in univariate analysis and 2.03 (95 % CI 1.13-3.66) in multivariate analysis. Similarly, the HRs for every increment of 40 pack-years which was the mean value among ever smokers were 2.79 (95 % CI 1.89-4.28) in univariate analysis and 2.39 (95 % CI 1.32-4.44) in multivariate analysis (Table 2) .
With the analysis restricted to males only, ATLL incidence was considerably higher for ever smokers than for never smokers; however, the correlation was not significant according to both univariate and multivariate analysis (HR 2.18, 95 % CI 0.48-9.96, HR 2.06, 95 % CI 0.45-9.47, respectively; Table 2 ).
With respect to the effects of smoking intensity, significant increasing risks of ATLL development according (Table 2) . With respect to the effects of drinking intensities, there were no significant increasing risks of ATLL development by increments of weekly alcohol intake in each multivariate analysis. The HRs for every increment of 300 g per weekly intake which was the mean amount among regular drinkers were 1.00 (95 % CI 0.55-2.46) in overall, 1.00 (95 % CI 0.55-2.46) in male, and 1.00 (95 % CI 0.30-35.8) in female groups (data not shown).
Discussion
To our knowledge, the present study is the first to prospectively examine the effects of cigarette smoking on ATLL development in a sub-cohort of HTLV-1 carriers within a long-term, large-scale Japanese prospective cohort. We found a significant positive association between smoking intensity and ATLL development among overall and male HTLV-1 carriers based on the number of cigarettes smoked per day and pack-years, but did not observe a significant difference between never smokers and ever smokers. Smoking intensities in male ever smokers were distributed over a wide range, i.e., the number of cigarettes per day ranged from 4 to 40 and pack-years from 1 to 195; therefore, we believed that the ever smokers did not all possess the same characteristics. In addition, with regard to the effect of cigarette smoking on the human body, we presume that those are probabilistic rather than deterministic; therefore, smoking intensity better represents the effects of smoking than smoking status (history).
Until now, the association between development of ATLL and cigarette smoking has been controversial. Tokudome et al. reported that smoking prevalence was significantly higher in ATLL cases than that in the general population and that there was a clear dose-response relationship between the amount (pack-years) of smoking and risk of ATLL development [23] . However, Hisada et al. reported that smoking prevalence did not differ significantly between ATLL cases and HTLV-1 carriers in their case-control study [24] . Our main finding of significantly increased hazard ratios for development of ATLL with smoking intensity (amount of cigarettes) supports those of Tokudome et al. [23] and suggests that smoking is a risk factor for ATLL development among HTLV-1 carriers.
Studies of cigarette smoking and risk of other lymphoid malignancies have yielded inconsistent results. Previously, Morton et al. [25] reported increased risk of non-Hodgkin lymphoma (NHL) with smoking in an international pooled analysis, whereas the association was not observed in a large-scale European study [26] . Recent studies on the etiologic heterogeneity of lymphoma subtype have investigated subtype-specific risks of lymphoma associated with smoking. For example, several studies reported that smoking was associated with increased risks of follicular lymphoma, but not for other NHL subtypes [25, 27] . Another pooled case-control study investigated the association between smoking and risk of Hodgkin lymphoma (HL) by subtype and identified a positive association between mixed cellularity and Epstein-Barr virus-positive HL [28] .
Other recent studies have reported that smoking is associated with increased risk of a higher incidence of T-cell lymphoma, but not of other NHL subtypes [29, 30] . Although they did not assess ATLL, their results may in part support our findings, since ATLL is a type of T-cell lymphoma. Unfortunately, the biological mechanism for the association between smoking and risk of T-cell malignancy remains unclear.
Although HTLV-1 infection alone is insufficient for ATLL development, specific genetic ATLL abnormalities that are additionally acquired (and required) have not been fully elucidated [31] [32] [33] . Moreover, it remains unknown whether these genetic abnormalities arise due to cigarette smoking or to HTLV-1 infection itself, and if they independently affect ATLL development. Whatever the reasons, our findings on the association between cigarette smoking and ATLL development suggest that quitting or decreasing smoking intensity, which is easily practicable in HTLV-1-endemic countries, may prevent ATLL development among the more than 10 million HTLV-1 carriers worldwide.
Our study had several strengths. First, the prospective design enabled us to evaluate the effects of cigarette smoking on the incidence rate of ATLL among HTLV-1 carriers for the first time, contrary to the majority of previous Japanese studies using cross-sectional designs [34] . The incidence rate of ATLL in the present cohort study, 1.08 (2.2 for men and 0.74 for women) per 1,000 personyears of HTLV-1 carriers, was consistent with a previous report [34] . In addition, our study design enabled us to minimize potential biases common in case-control studies, such as recall and selection biases. Second, the JPHC study employed detailed follow-up procedures and had virtually complete ascertainment of incident ATLL cases because of the high precision of the cancer registry system in this study. The proportion of death certification only (DCO) was only 8 %.
Some limitations of our study should be discussed. First, the present study had a small sample size, which limited our power to examine the effects of smoking on ATLL development, especially in female HTLV-1 carries, whose smoking status was skewed toward never smokers. Additional large-scale, prospective studies are necessary to confirm our results. Second, we did not evaluate ATLL development according to known risk markers, such as soluble interleukin 2 receptors (IL-2R) levels and proviral load [15, 16] . Therefore, studies specific to ATLL in HTLV-1 carriers that include these risk markers are needed to determine whether smoking is a significant risk factor in addition to existing risk markers. Third, smoking habits were assessed by means of self-administered questionnaires, which could have introduced exposure misclassification and resulted in underestimation of risk. However, a recent study indicated that self-reported smoking habits were substantially reliable [35] . Finally, smoking and drinking habits were evaluated only at baseline in a survey that lasted an average of 17 years. Therefore, the possibility of confounding by change in these habits cannot be ruled out.
In conclusion, the results of this study indicate that cigarette smoking may influence ATLL development among HTLV-1 carriers in Japan.
